September 1, 2016Nature
A paper published August 31 in Nature, describes that Biogen Idec’s candidate treatment, aducanumab, reduced amyloid-β in the brains of patients with early-stage Alzheimer’s disease. Patients receiving the highest doses of the medicine in the Phase IB trial had the largest reductions in brain amyloid and also declined the least in clinical assessments.
These are promising results that will require replication in larger clinical trials, which have recently launched, including at UCI MIND.
Read the Nature news article about the study here.
